Share and Follow
- The WHO has recommended the use of a second malaria vaccine for children.
- The vaccine, known as R21/Matrix-M, will begin to be rolled out in mid-2024.
- R21/Matrix-M is mass manufactured by India’s Serum Institute.
“Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease.”
“Demand for the RTS,S vaccine far exceeds supply, so this second vaccine is a vital additional tool to protect more children faster, and to bring us closer to our vision of a malaria-free future.”
Over 20 million doses have already been produced by Serum Institute
The vaccine will compete against the RTS,S shot by GSK Plc (GSK.L), which was recommended by the United Nations agency in 2021 and sold under the brand Mosquirix.
Nearly half a million children in the African region die every year from Malaria.